US20020168670A1

US20020168670A1 - Identification of disease predictive nucleic acids

Info

Publication number: US20020168670A1
Application number: US10/109,213
Authority: US
Inventors: David Ecker
Original assignee: Isis Pharmaceuticals Inc
Current assignee: Ionis Pharmaceuticals Inc
Priority date: 1998-11-25
Filing date: 2002-03-27
Publication date: 2002-11-14
Also published as: US6451524B1

Abstract

The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of preselected disease states or biological conditions in cells containing the nucleic acid sequence. Members of a set of mRNA molecules from a common gene, but containing different sequences and structures, are compared. The gene is predictive of the disease state or biological condition in cells containing the gene. At least one molecular interaction site from among those present in the members of the set are identified. The molecular interaction site is present in cells likely to have the disease state or biological condition. At least one nucleic acid sequence from the molecular interaction site is ascertained.

Description

FIELD OF THE INVENTION

The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of disease states or biological conditions in cells containing the nucleic acid sequence.

BACKGROUND OF THE INVENTION

Recent advances in genomics, molecular biology, and structural biology have highlighted how RNA molecules participate in or control many of the events required to express proteins in cells. Rather than function as simple intermediaries, RNA molecules actively regulate their own transcription from DNA, splice and edit mRNA molecules and tRNA molecules, synthesize peptide bonds in the ribosome, catalyze the migration of nascent proteins to the cell membrane, and provide fine control over the rate of translation of messages. RNA molecules can adopt a variety of unique structural motifs, which provide the framework required to perform these functions.

The many functions of RNA molecules has also solidified their importance as therapeutic drug and diagnostic targets. Indeed, many investigators are pursuing mRNA transcripts and proteins produced therefrom that are expressed at different levels in cancer vs. normal cells in order to develop therapeutic and/or diagnostic compounds which modulate the cancer-causing mRNA transcript or protein. Indeed, 500 transcripts have been reported to be expressed at significantly different levels (15-fold on average) in normal vs. gastrointestinal tumor cells. Zhang, et al., Science, 1997, 276, 1268-72. Many genes have as many as 10-20 alternative transcript forms that, in some cases, have been associated with a cancer phenotype. For example in cancerous cells, transcription of the mdm2 gene is initiated at a distinct site not used in normal cells. Landers, et al., Cancer Res., 1997, 5,, 3562-3568, incorporated herein by reference in its entirety. In the Bcl-x mRNA, alternatively spliced forms of the transcript result in dramatically different cell behavior and sensitivity to chemotherapeutic drugs. Kuhl, et al., Br. J Cancer, 1997, 75, 268-274, which is incorporated herein by reference in its entirety.

A universal technology platform to attack multiple forms of cancer has widely been believed to be impossible due to the heterogeneous nature of cancer. Thus, traditional cancer therapeutics has focused on individual cancer pathways and modulation of individual proteins and/or MRNA transcripts associated with the suspected causative pathway of the disease state. An unconventional, broadly applicable approach to cancer diagnosis and treatment, however, is greatly desired. Accordingly, the present invention provides the means to identify distinguishing features of types of cancer coupled with a common molecular mechanism to diagnose and selectively destroy the cancer cells or other cells associated with a disease state or biological condition. It is a principal object of the invention to identify a target nucleic acid sequence which is predictive of a disease state or biological condition in cells containing the nucleic acid sequence.

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an example of a 3′-EST cluster. [0006]
FIG. 2 illustrates alternative initiation of mdm2 gene in cancer and normal cells results in unique RNA structures. [0007]
FIG. 3 illustrates Her 2 alternative transcript forms. [0008]
The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of preselected disease states or biological conditions, especially cancer, in cells containing the nucleic acid sequence. Members of a set of mRNA molecules from a common gene, but containing different sequences and structures, are compared. The set of mRNA molecules from a common gene, but containing different sequences and structures are referred to as “alternative transcript forms. ” Comparison of the alternative transcript forms provides for the identification of at least one alternative transcript form which is associated with the disease state or biological condition. The alternative transcript form, or the protein which is encoded by the same, is not required to be directly involved in any pathogenesis pathway. For example, the alternative transcript form may be merely a marker for the disease state or biological condition without participating or being required for establishment or maintenance of the disease state or biological condition. For example, the alternative transcript form or protein encoded thereby may be a by-product of the pathogenesis involved in the disease state or biological condition. Once an alternative transcript form, which is associated with-a disease state or biological condition is identified, the molecular interaction site, or cancer signature, for example, can be identified by the methods described herein. The molecular interaction site is unique to the alternative transcription form which is associated with the disease state or biological condition. The alternative transcription forms which are not associated with a disease state or biological condition do not contain the identified molecular interaction site. Once the molecular interaction site is identified, additional alternative transcript forms from a variety of genes can be analyzed to determine whether they comprise the same molecular interaction site. In this manner, additional mRNA molecules can be identified which may also be predictive of a disease state. [0009]
Alternative transcript fomis originate from alternative initiation of transcription, alternative splicing, alternative 3′-end processing or a combination of these mechanisms. Alternative 3′-end processing may be the greatest source of alternative transcript forms. Studying 160,000 EST sequences, D. Gautheret and collaborators have shown that from 20-40% of the transcripts have two or more different 3′-ends (See FIG. 1) Gautheret, [0010] Genome Res., 1998, 8, 524-530, which is incorporated herein by reference in its entirety. Other investigators have shown that certain classes of mRNAs are alternatively 3′- endprocessed inatissue-specific ordevelopmentally-specificpattem Edwalds-Gilbert, Nuci. Acids. Res., 1997, 25, 2547-2561, which is incorporated herein by reference in its entirety) and in some cases this has been correlated with cancer. For example, the mss4 transcript was recently shown to have alternative 3′-end processing in pancreatic cancer. Muller-Pillasch, Genomics, 1887, 46, 389-396, which is incorporated herein by reference in its entirety. Alternative 3′-end formation does not change the protein composition, but can dramatically influence message stability and regulate translation by including or excluding regulatory sequences in the mRNA transcript.
Alternative transcript forms, despite being transcribed from identical DNA and translated into identical proteins possess unique sequences and three-dimensional shapes that exist only at the level of RNA. A very important consequence of alternative transcript forms for cancer recognition is the unique shapes that they adopt. In contrast to the regular, helical nature of DNA, RNA strands form intricate stems, loops, and Bulges, which are arranged into three-dimensional shapes that rival proteins in their complexity. Alternative transcript forms can produce different shapes in several ways. First, with alternative transcription initiation or 3′-end formation, there are unique sequences in mRNAs that do not appear at all in the normal mRNA (See, FIG. 2). These sequences, in turn, will fold into unique structures within themselves and with the adjacent RNA. Second, each alternative splicing event can produce a unique junction, in which the adjacent RNA on each side of the junction will re-arrange into a new three-dimensional shape. [0011]
Alternative transcript forms are distinguishable from cancer-specific expression of transcripts. Cancer-specific transcripts provide a perfectly useful set of moleculartargets forthe invention described herein. However, the greater opportunity to find useful cancer signatures is in alternative transcript forms since there may be 2-20 different forms of every transcript and 10-20,000 genes expressed in any given cell. Thus, the opportunity to find cancer-specific alternative transcript forms may be much greater than for cancer-specific transcripts. Whether the origin of the cancer signature comes from cancer- specific transcripts or cancer-specific transcript forms, for the technology of the present invention it is not required that the cancer-specific differences in mRNA be responsible for cancer phenotype. It is not even important that it is known what they do. The important point is that they are present in cancer cells and can therefore be used to mark them for destruction. Accordingly, the presented invention is directed, in part, to identifying at least one molecular interaction site within at least one alternative transcript form which is associated with the disease state or biological condition. [0012]
Alternative transcript forms and their association to particular disease states or conditions are known to one skilled in the art. For example, alternative transcript forms known to those skilled in the art are shown in Table 1 below and are described in more detail in Edwalds-Gilbert, [0013] Nucl. Acids. Res., 1997, 25, 2547-2561, which is incorporated herein by reference in its entirety. Any of the alternative transcript forms listed in Table 1, Table 2, and Table 3 can be used to identify molecular interaction sites as set forth below. Table 1 shows numerous examples of transcription units with multiple poly(A) sites, all within a single 3′- terminal exon. Included in Table 1 are those genes for which there is solid evidence for more than one RNA species. Two other major classes of gene organization leading to the generation of alternative poly(A) sites on mRNA are listed in Tables 2 and 3. The final protein products of both types of genes can differ at their C-termini depending on which processing pathway is followed. Exons are generally categorized as 5′-terminal, internal or 3′-terminal with polyadenylation signals in the UTR.

A number ofgenes listed in Table 2 contain composite exons in which 5′ splice sites can sometimes be silent, causing them to behave as 3′-terminal exons, or sometimes be active, thereby causing them to behave as internal exons, depending on the tissues in which the gene is expressed; these we call composite, in/terminal exons. Genes like the immunoglobulin heavy chains have an exon serving either as the first 3′-terninal exon in one mRNA (use of pAl) or as an internal exon in a second mRNAwhich ends with a normal 3′-terminal exon found further downstream (use of pA2). The primary transcript from other genes like calcitonin/calcitonin gene-related peptide, listed in Table 3, are processed into two mRNAs by using either the first alternative 3′-terminal exon with its poly(A) site (pAl) or skipping that exon entirely and splicing the second 3′-terminal exon into the transcript, using pA2 instead. The distance between the poly(A) sites in these two classes of genes can be quite large (>3 kb in Ig genes) and differential sites of transcription termination, between the poly(A) sites, could change the distribution of 3′-end use in mRNA. Levels of basal polyadenylation factors, splicing factors and termination factors could all contribute cell type-specific mechanisms leading to 3′-end formation.

TABLE 1


Genes with alternative tandem poly(A) sites in the 3′-UTR

		Notable
	Regulatory	features
Gene	element^a	Where seen	Comments

23 kDa Trans-		Brain, retina	From the P198 gene,
plantation antigen			which is highly con-
α-Galactosidase A			served [including the
			poly(A) sites] across
			mammalian species;
			two poly(A) sites
			Mouse; three poly(A)
			sites, two mRNAs
Acetylcholinesterase		Muscle,	Mouse, human; two
		brain	poly(A) sites; second
			site predominates in
			muscle, first site
			predominates in brain
Activin βA subunit		TPA	Human; eight possible
		treatment	poly(A) sites; treat-
			ment of HT1080 fibro-
			sarcoma cells with
			TPA causes a shift
			over time to use of
			proximal poly(A) site
ADP ribosylation	3 (ARF 4)	Testes	ARF	1 has two
factor (ARF)			poly(A) sites con-
			served in human and
			rat. ARF 4 makes a
			short, testes-specific
			mRNA generated by
			alternative
			polyadenylation
Aldolase B			Mouse; one non-
			canonical and three
			canonical poly(A)
			sites, use of all four
			sites detectable in liver
			and kidney
Amphiglycan		Chondro-	At least two poly(A)
(syndecan 4,		cytes	signals; longer
ryudocan)			message is ubiquitous,
			shorter is tissue-
			specific switch in
			poly(A) site use during
			chondrocyte
			differentiation
Amyloid protein	2, 4		Sequence between two
			poly(A) sites increases
			translation of the
			longer mRNA
Androgen receptor			Human; two poly(A)
			sites, the first is
			AUUAAA and the
			second is CAUAAA
Angiotensin		Testes,	Rabbit; testes- versus
converting enzyme		pulmonary	pulmonary-specific
(ACE)		tissue	forms
Ankyrin-1		Brain	Mouse; both poly(A)
			sites used in erythroid
			tissues, distal site used
			in cerebellum
Apolipoprotein B		Intestine	Putative cryptic
			poly(A) site improved
			by editing
Arylsulfatase A			Mutation of first
			poly(A) signal seen in
			arylsulfatase A
			pseudodeficiency
Axonin-1		Retina, brain	Chicken; three poly(A)
			sites
β-Tubulin		HSV	Changes in the ratio of
		infection	the two forms occur
			during HSV infection
β2-Microglobulin			Murine; two poly(A)
			sites
β3-Adrenergic			Human; rat two
receptor			poly(A) sites
Band 7.2b gene		Many cell	Human; integral
		types	membrane phospho-
			protein; distal site
			predominates in all
			tissues, proximal site
			use is significant in
			lung, liver and kidney
			and minimal in spleen
Brain-derived		Heart, lung,	Rat; isoform pro-
neurotrophic factor		brain	duction controlled by
(BDNF)			alternative splicing;
			multiple promoters
			used; two poly(A)
			sites, ratio of
			proximal; distal site
			use varies among
			heart, lung, cerebral
			cortex
Cationic amino acid	1	Cell density	Rat; relative con-
transporter gene			centration of two
(cat-1)			mRNAs is regulated
			by cell density
c-Mos	3		Porcine; protoonco-
			gene whose expression
			is restricted to gonadal
			tissues in the pig;
			alternative polyadenyl-
			ation may play a role
			in translation
CD40	3	Differ-	murine; differential
		entiation	poly(A) site use during
			B lymphocyte
			activation
CD59 (membrane	3	Many cell	Human, complement
inhibitor of reactive		types	regulatory protein;
lysis)			four possible poly(A)
			sites; use of two
			poly(A) sites varies in
			different cell lines
Chymotrypsin-like			Human chromosome
protease			16q22.1; alternative
			polyadenylation
			creates transcription
			unit which overlaps
			with oppositely
			oriented gene
Clathrin heavy chain	3	Develop-	Mosquito; poly(A) site
gene		mental	use differs between
		changes	somatic cells and
			germ cells
Collagenase 3			Human; three mRNAs
			seen in mammary
			carcinoma cells
cAMP-responsive	1	Testes	Follicle-stimulating
element modulator			hormone regulates
(CREM)			CREM expression in
			testes by changing
			poly(A) site use,
			causing an increase in
			mRNA stability
Cyclin D1		Develop-	Human, mouse, zebra-
		mental	fish; two poly(A) sites;
		changes	change in poly(A) site
			use during zebrafish
			embryonic develop-
			ment; one major and
			two minor forms found
			in HeLa and all hema-
			topoetic cells tested
Cyclooxygenase-1			Human; two poly(A)
(COX-1)			sites
Cyclooxygenase-2	1	Dexa-	Expression induced by
(COX-2)		methasone	cytokines; three
		treatment	poly(A) sites; dexa-
			methasone treatment
			selectively destabilizes
			longer mRNA
Cytochrome P450		Many cell	Human; two poly(A)
aromatase		types	sites, [second poly(A)
			signal AUUAAA];
			mouse, porcine,
			equine; two poly(A)
			sites. 2.5 kb mRNA
			predominant in ovaries
Cytochrome P450-			Mouse; two poly(A)
linked ferredoxin			sites
Dihydrofolate		Cell cycle	Seven poly(A) sites;
reductase (DHFR)			promoter-proximal site
			used during growth
			stimulation
Dipeptidyl peptidase			Mouse; two poly(A)
IV (CD26)			sites in exon 26,
			proximal poly(A) site
			predominates in all
			tissues examined
DNA polymerase β	3	Testes;	Rat; the 1.4 kb
		brain	transcript pre-
			dominates in testes and
			has a poly(A) signal
			AAUGAA; 4 kb
			transcript
			predominates in brain
eIF-2α ( translation	1, 4	Testes	Two poly(A) sites;
initiation factor 2α)			different ratio in
			different tissues; the
			longer mRNA is more
			stable in activated T
			cells; the shorter
			mRNA has increased
			translatablilty; third
			poly(A) site used in
			testes
eIF-4E (translation		Many cell	Mouse; multiple
initiation factor 4E)		types	poly(A) signals; 1.8 kb
			transcript pre-
			dominates in mouse
			kidney and liver and in
			a pre-B cell line, S194.
			A 1.5 kb transcript is
			abundant in mouse
			thymus and in S194
			cells. Minor mRNAs
			of 2.2 and 2.5 kb
			correspond to use of
			alternate poly(A)
			signals as well
eIF-5 (translation		Testes	Mammalian; proximal
initiation factor 5)			poly(A) site used pre-
			dominantly in testes,
			distal site favored in
			other tissues examined
Excision repair gene		Testes	Human; presumed
ERCC6			helicase; two poly(A)
			signals, first is
			AUUAAA; shorter
			mRNA is primarily
			expressed in testes
Fanconi anemia	3		Human; three poly(A)
group C (FACC)			sites, longest transcript
			is most abundant and
			its poly(A) signal is
			AAUAAA; first two
			poly(A) signals are
			non-canonical; longest
			transcript contains a
			series of direct 35 bp
			repeats preceded by a
			12 bp palindrome
Ferritin heavy chain		Many cell	Human; two poly(A)
		types	signals; tissue-specific
			differences in ratio of
			use (brain, skeletal
			muscle versus
			placenta, liver,
			pancreas)
Fibroblast growth	2	Retinoic acid	Mouse; both mRNAs
factor (int-2)		treatment	inducible in F9 cell
			line by treatment with
			retinoic acid
Basic fibroblast	2	Cell density	Use of two poly(A)
growth factor			sites varies with cell
(bFGF)			density
Fibroglycan			Human; at least two
(syndecan 2)			functional poly(A)
			signals
FMR1			Fragile X gene; two
			poly(A) sites
G protein γ subunit	3	Many cell	Drosophila; use of
(D—G γ1)		types	three different poly(A)
			sites is develop-
			mentally regulated and
			cell type specifc; 2.6
			kb transcript found in
			head. 1.3 kb transcript
			found in body, 1.1 kb
			transcript more
			abundant in head than
			in body
Gastric capthesin E			Human aspartic pro-
			lease; two poly(A)
			sites
GATA-2			Transcription factor;
			two poly(A) sites
Grg			Murine; related to the
			groucho transcript of
			the Drosophila
			Enhancer of split
			complex
Growth hormone			Alternative poly(A)
receptor, avian			site in exon 5
			generates short form,
			in the absence of
			alternative splicing,
			unlike mammalian
			counterpart
Heparan sulfate		Liver,	Rat; major cell surface
proteoglycan		kidney	heparan sulfate
			proteoglycan; three
			poly(A) sites used in
			most tissues, most
			proximal site used
			only in liver and
			kidney
Herpes simplex			Increased polyadenyl-
virus type 1			ation at weak viral
(HSV-1) UL24			sites via effects on
			host cell CstF 64-kDa
High mobility group			Murine; three poly(A)
1 protein (HMG1)			sites
Histone HI
⁰	1	Butyrate	Mouse; differentiation-
		treatment	specific histone HI;
			two mRNAs, first
			poly(A) signal is
			AUUAAA; minor 0.9
			kb mRNA becomes
			more stable during
			butyrate-induced
			dedifferentiation.
			mRNAs equally stable
			after treatment with
			actinomycin D
Huntington disease		Brain	Use of distal poly(A)
gene			site predominates in
			brain; most other
			tissues favor proximal
			poly(A) site
Integrin α5			Xenopus laevis;
			alternative
			polyadenylation occurs
			in the embryo
Interleukin-8			Human; two mRNAs
receptor α			equally abundant in
			neutrophils
Iron regulatory		Intracellular	Human, rat; RNA
protein 2 (IRP2)		iron levels	binding protein whose
			affinity for its binding
			site is modulated by
			intracellular iron
			levels; increase in
			proximal poly(A) site
			use with reciprocal
			decrease in distal
			poly(A) site use in
			iron-depleted cells
Ketohexokinase			Human; two poly(A)
(fructokinase)			sites; second is
			GAUAAA
Lamin B3		Testes	Mouse; germ cell
			(testes) specific RNA
			processing of lamin B2
			generates lamin B3
Lipoprotein lipase	2	Many cell	Human; longer
		types	transcript pre-
			dominates in skeletal
			and cardiac muscle;
			adipose tissue
			produces both forms of
			mRNA; longer
			transcript translated
			more efficiently than
			short one
Long chain acyl-		Many cell	Mouse; two poly(A)
CoA dehydrogenase		types	sites
(ACAD 1)
Manganese		Many cell	Rat; five poly(A) sites;
superoxide		types	first two sites used in
dismutase			all tissues tested;
			proximal poly(A) site
			predominates in testes
			and liver, distal site
			used in heart, lung and
			kidney
Microtubule-		Many cell	Mouse; 3′-UTR well
associated protein		types	conserved between
4 (MAP4)			mouse and human;
			first two sites used in
			all tissues tested; third
			site used in muscle;
			fourth site used in
			testes, but first site
			predominates
Mitochondrial	3		Rat; two poly(A) sites;
HMG-CoA synthase			AUUAAA and
			AUUAUC
N-Formyl peptide		Dibutryl	Human; two-exon
receptor (FMLF-R)		cAMP	gene, at least two
		treatment	poly(A) sites; pre-
			dominant use of
			proximal poly(A) site
			after treatment of
			HL60 human
			lymphoma cells with
			the differentiation
			agent dibutryl cAMP
NAD(P)H:quinone	3	Mitomycin C	Human colon cancer
oxidoreductase		treatment	HCT 116 cells; two
			mRNAs; change in
			ratio after mitomycin
			C treatment
Non-muscle myosin			Human; two poly(A)
heavy chain			sites
mal-1			Mouse; novel
			keratinocyte lipid-
			binding protein; tumor
			specific over-
			expression; two
			poly(A) sites, use of
			first one predominates
P-selectin			Human, chromosome
glycoprotein ligand			12q24; major mRNA
			species 2.5 kb, minor
			species 4 kb
Paramyosin		Develop-	Drosophila; use of two
		mental	poly(A) sites is
		changes	developmentally
			regulated
Phosphofructokinase		Develop-	Drosophila; use of
(PFK)		mental	three poly(A) sites is
		changes	developmentally
			regulated
Platelet-derived			Three poly(A) signals
growth factor
(PDGF)
PR264/SC35	1	Many cell	Human splicing factor;
		types	ratio of different forms
			varies among six
			different cell lines
			tested
rab2	2	Many cell	Human Ras-related
		types	GTP binding protein;
			three potential poly(A)
			signals
RanGAP1		Testes	Human; activator of
			Ras-related nuclear
			GTPase Ran, shows
			testes-specific
			polyadenylation
Renal glutaminase		Many cell	Rat; ratio of poly(A)
			site use varies in
			different cell lines
RHOA	2	types	Human Ras-related
protooncogene			GTP binding protein;
			found in breast cancer
			cell lines; three
			poly(A) sites
Senescence marker			Rat; two poly(A) sites
protein-30
(SMP-30)
set, putative		Many cell	Human, mouse; ratio
oncogene associated		types	of two mRNAs varies
with myeloid			in different cell types
leukemogenesis			and five cell lines
			tested; shorter mRNA
			predominates in liver
			and kidney
Soluble angiotensin	3		Porcine; two poly(A)
binding protein			sites, first is
			GAUAAA; longer
			transcript may be
			regulated by SINE
			element in 3′-UTR
Splicing factor 9G8		Many cell	Human; two poly(A)
		types	sites; pre-mRNA also
			subjected to alternative
			splicing
Steel	3		Murine; encodes stem
			cell factor (SCF);
			distal poly(A) site used
			predominantly; 3′-UTR
			is 4.4 kb
Suppressor of			Drosophila; three
forked su(f)			mRNAs
Syndecan-1			Mouse; two poly(A)
			sites
Tissue inhibitor of	2		Human; two stable
metalloproteinases-2			transcripts
(TIMP-2)
Tissue inhibitor of		TPA	Murine; three
metalloproteinases-3		treatment	transcripts of 2.3, 2.8
(TIMP-3)			and 4.6 kb. 4.6 kb
			most abundant. All
			three transcripts
			induced in pre-
			neoplastic JB6 cells
			treated with TPA
Transforming	3		Human; five possible
growth factor alpha			poly(A) sites but only
(TOP α)			two mRNAs detected;
			use of distal poly(A)
			site (AAUGAA)
			predominates in most
			tissues
Triose phosphate
	3	Testes	Rat; 1.4 kb mRNA
isomerase			found in most tissues
			and in somatic cells of
			testes; its level
			increases after retinol
			treatment; the 1.5 kb
			species is detected
			only in haploid
			spermatids
Tryptophanyl-tRNA			Murine, human; two
synthetase			poly(A) sites, first is
			AAUCAA
Tubulin			Trypanosomes;
polycistronic			transcription unit
pre-mRNA			undergoes trans-
			splicing and alternative
			polyadenylation,
			which may be coupled
			in this system
Vascular endothelial	1	Hypoxia	Rat; two poly(A) sites;
growth factor			regulation of poly(A)
(VEGF)			site use by hypoxia
WNT-5A			Human; expression in
			early embryogenesis
ZAKI-4	2	Many cell	Human thyroid
		types	hormone-responsive
			gene; two mRNAs,
			first poly(A) signal is
			AUUAAA; short
			mRNA predominates
			in heart and brain,
			trace amounts found in
			liver; long mRNA
			predominates in
			skeletal muscle; no
			messages detected in
			placenta, lung, kidney,
			pancreas

TABLE 2


Genes with multiple poly(A) sites in competition
with splice sites; composite ‘in/terminal’ exons

Gene	Notes on regulation

(2′-5′) Oligo	Transcription induced by interferon-β; distal poly(A) site
A synthetase	favored after induction; proximal poly(A) site used
	predominantly during basal transcription
α-Spectrin	Proximal poly(A) site used exclusively in erythroid cells;
	default pattern of pre-mRNA processing uses distal
	poly(A) site
C3b/C4b	Use of proximal poly(A) site yields secreted form of
receptor	receptor; predominant membrane-bound receptor is
(complement	generated by use of distal poly(A) site
receptor
type I)
Cek5	Chicken receptor protein-tyrosine kinase of the Eph
	subfamily; use of the proximal poly(A) site yields
	secreted form of kinase, whose expression is low relative
	to the full-length Cek5 receptor
Epidermal	Proximal poly(A) site leads to production of secreted
growth factor	form of receptor, which can inhibit the activities of the
(EGF) receptor;	membrane-bound receptor
human, chicken
exuperantia	Drosophila gene required for both oogenesis and
(exu)	spermatogenesis that undergoes sex-specific alternative
	pre-mRNA processing; tra-2 gene required for male-
	specific RNA processing
Fibrinogen	Rat pre-mRNA undergoes liver-specific choice of
γ-chain	proximal poly(A) site; other cell types always use distal
	poly(A) site
Fibroblast	Secreted form of receptor generated by use of the
growth factor	proximal poly(A) site; membrane-bound forms are
(FGF) receptor	produced by use of distal poly(A) site; secreted form also
	binds FGF
GARS/AIRS/	Glycinamide ribonucleotide synthetase (GARS)/
GART	aminoamidazole ribonucleotide synthetase(AIRS)/
	glycinamide ribonucleotide formyltransferase (GART);
	enzyme required for purine synthesis; use of proximal
	site corresponds to production of the monofunctional
	enzyme; use of the distal site yields the trifunctional
	enzyme; all tissues examined favor distal poly(A) site
Glucocorticoid	β form of receptor produced by use of the proximal
receptor	poly(A) site; more abundant α form uses the distal
	poly(A) site
HER2/	Protein tyrosine kinase receptor in which membrane-
neu receptor	bound form is produced from mRNA using the distal
	poly(A) site; use of proximal poly(A) site leads to
	shorter, intracellular form of the receptor. use of the
	proximal and distal poly(A) sites varies greatly in
	different tumor cell lines
Hepatocyte	Hepatocyte nuclear factor homeoprotein family important
nuclear factor	for liver-specific expression of a number of genes;
(HNF1/	poly(A) site choice and intron inclusion contribute to the
vHNF1)	generation of HNF1 isoforms, all of which contain
	different C-terminal domains, have distinct effects on
	transcription and can form homo- and heterodimers;
	mRNA levels for these isoforms vary in different tissue
	types and in some fetal versus adult tissues
Ig α heavy	Use of proximal poly(A) site produces mRNA encoding
chain	secreted form of antibody; use of the distal poly(A) site
	generates mRNA for membrane-bound antigen receptor;
	secretory-specific mRNA dominant in plasma cells
	whereas there are equal amounts of the two mRNAs in
	mature or memory B cells
Ig ε heavy	Pattern of regulation similar to Ig α heavy chain
chain	pre-mRNAs
Ig γ heavy	Pattern of regulation similar to Ig α heavy chain
chain	pre-mRNAs
Ig μ heavy	Pattern of regulation similar to Ig α and to other Ig heavy
chain	chain pre-mRNAs; can also include transcription
	termination as a mechanism of proximal poly(A) site
	selection
Leukemia	Member of hemopotetin receptor family; murine gene
inhibitory	produces a secreted [proximal poly(A) site] and
factor receptor	membrane-bound form [distal poly(A) site], with increase
α-chain	in the secreted form during pregnancy
Nuclear factor	Distal poly(A) site favored in all tissues examined,
I-B3	proximal poly(A) site used in heart and skeletal muscle;
	protein encoded by the shorter mRNA acts as a
	transcriptional repressor
Plasma	Use of proximal poly(A) site specific to skeletal muscle
membrane	and brain
Ca⁺²-ATPase
isoform 3
Poly(A)	Component of polyadenylation complex; six isoforms
polymerase	generated via alternative splicing and polyadenylation;
	some isoforms found in all tissues examined, others show
	tissue-specific expression; use of one of three proximal
	poly(A) sites yields forms that contain the polymerase
	domain but not the serine/threonine-rich domain and
	nuclear localization signal (see also Table 3)
Sarco/	Five protein isoforms are generated from three different
endoplasmic	SERCA genes plus alternative processing events;
reticulum	regulation of expression is both developmental and tissue
Ca²⁺-ATPase	specific and is suggested to be at the level of splicing
(SERCA)	rather than polyadenylation; two SERCA2 protein
	isoforms are translated from four different mRNAs
	generated by tissue-dependent alternative processing,
	one of which is brain specific; SERCA2a protein is
	muscle specific. SERCA2b is found in non-muscle
	tissues and smooth muscle
Secretory PLA₂	Receptor has similar structural organization to
receptor	macrophage mannose receptor; acts as a mediator of
	inflammatory processes; secreted form of
	phospholipaseA₂receptor found in human kidney;
	membrane bound receptor is widely expressed, including
	in kidney
Thyroid	Proximal poly(A) site yields α1, which binds thyroid
hormone	hormone; distal poly(A) site produces α2, which cannot
receptor α	bind thyroid hormone; ratio of two mRNAs varies in
(c-erbA-1)	different tissues. α2 transcript overlaps with gene
	transcribed in opposite direction. Rev-ErbAα

TABLE 3


Genes with multiple alternative 3′-terminal exons; skipped exons

Gene	Notes on regulation

α-Tropomyosin	At least four poly(A) sites; proximal poly(A) site used in
	striated muscle and distal poly(A) site used in smooth
	muscle and fibroblasts; three of the poly(A) sites used in
	brain
Adenovirus	Five poly(A) sites; the proximal poly(A) site, L1, used
major late	predominantly in early infection; L3 dominates late in
transcription	infection
unit
β-Tropomyosin	Proximal poly(A) site used exclusively in skeletal
	muscle; other cell types use the distal poly(A) site;
	regulation may be at the level of splice site choice
Calcitonin/	Proximal poly(A) site used in most cell types, generating
calcitonin	the mRNA for calcitonin; distal poly(A) site used
gene-related	exclusively in neuronal cells, leading to production
peptide	of CGRP
(CGRP)
doublesex (dsx)	Drosophila gene required for somatic sexual
	differentiation that undergoes sex-specific alternative
	pre-mRNA processing; tra-2 protein required for
	regulated RNA processing and acts through its binding
	site in the dsx pre-mRNA
Epidermal	Proximal poly(A) site leads to production of secreted
growth factor	form of receptor, which can inhibit the activities of the
(EGF) receptor;	membrane-bound receptor; differs from human and
rat	chicken isoforms (see Table 2)
FLT4 receptor	Ratio of the mRNAs using the proximal or distal poly(A)
tyrosine kinase	site varies in different cell lines
Neural cell	Ratio of the mRNAs produced varies in different cell
adhesion	types
molecule
(NCAM)
Plasma α(1,3)-	Two poly(A) sites are used equally in liver; proximal
fucosyltrans-	poly(A) site favored in colon; distal poly(A) site used
ferase (FUT6)	predominantly in kidney
Poly(A)	Component of polyadenylation complex; six isoforms
polymerase	generated via alternative splicing and polyadenylation;
	some isoforms found in all tissues examined, others show
	tissue-specific expression; use of one of three proximal
	poly(A) sites yields forms that contain the polymerase
	domain but not the serine/threonine-rich domain and
	nuclear localization signal (three exons also composite;
	see Table 2)
Unique human	Spans over 230 kb in human chromosome Sp11-12;
gene of	codes multiple proteins sharing RNA binding motifs
unknown
function

The present invention is directed to identifying a target nucleic acid sequence which is predictive of a preselected disease state or biological condition. The disease states or biological conditions include, but are not limited to, nucleic acids known to be important during inflammation, cardiovascular disease, pain, cancer, arthritis, trauma, obesity, Huntingtons, neurological disorders, hyperproliferative conditions, neoplastic states or conditions, Lupus erythematosis, and many other diseases or disorders. [0017]
From analysis of Expressed Sequenced Tags (ESTs), it has been found that mRNA transcripts are much more heterogeneous than previously anticipated. Alternative transcript forms of mRNA molecules can be identified by using ESTs from a variety of databases. For example, preferred databases include, for example, Online Mendelian Inheritance in Man (OMIM), the Cancer Genome Anatomy Project (CGAP), GenBank, EMBL, PR, SWISS-PROT, and the like. OMIM, which is a database of genetic mutations associated with disease, was developed, in part, for the National Center for Biotechnology Information (NCBI). OMIM can be accessed through the Internet at, for example, [0018] http://www.ncbi.nlm.nih.gov/Omim/. CGAP, which is an interdisciplinary program to establish the information and technological tools required to decipher the molecular anatomy of a cancer cell. CGAP can be accessed through the Internet at, for example, http://www.ncbi.nlm.nih.zov/ncicgap/. Some of these databases may contain complete or partial nucleotide sequences. In addition, alternative transcript forms can also be selected from private genetic databases. Alternatively, alternative transcript forms can be selected from available publications or can be determined especially for use in connection with the present invention.
After an alternative transcript form is selected or provided, the nucleotide sequence of the alternative transcript form preferably is determined. In one embodiment of the invention, the nucleotide sequence of the nucleic acid target is determined by scanning at least one genetic database or is identified in available publications. Preferred databases known and available to those skilled in the art include, for example, the Expressed Gene Anatomy Database (EGAD) and Unigene-Homo Sapiens database (Unigene), GenBank, and the like. EGAD contains a non-redundant set of human transcript (HT) sequences and can be accessed through the Internet at, for example, [0019] http://www.tigr.org/tdb/egad/egad.html.Unigene is a system for automatically partitioning GenBank sequences into a non-redundant set ofgene-oriented clusters. Each Unigene cluster contains sequences that represent a unique gene, as well as related information such as the tissue types in which the gene has been expressed and map location.
In addition, Unigene contains hundreds of thousands of novel expressed sequencetag (EST) sequences. Unigene can be accessed through the Internet at, for example, [0020] http://www.ncbi.nlm.nih.gov/UniGene/. These databases can be used in connection with searching programs such as, for example, Entrez, which is known and available to those skilled in the art, and the like. Entrez can be accessed through the Internet at, for example, httD://www.ncbi.nlm.nih.gov/Entrez/. Preferably, the most complete nucleic acid sequence representation available from various databases is used. The GenBank database, which is known and available to those skilled in the art, can also be used to obtain the most complete nucleotide sequence. GenBank is the NIH genetic sequence database and is an annotated collection of all publicly available DNA sequences. GenBank is described in, for example, Nuc. Acids Res., 1998, 26, 1-7, which is incorporated herein by reference in its entirety, and can be accessed by those skilled in the art through the Internet at, for example, http://www.ncbi.nlm.nih.gov/Web/Genbank/index.html. Alternatively, partial nucleotide sequences of nucleic acid targets can be used when a complete nucleotide sequence is not available.
Alternative transcript forms can be generated from individual ESTs which are within each of the databases by computer software which generates contiguous sequences. In another embodiment of the present invention, the nucleotide sequence of the nucleic acid target is determined by assembling a plurality of overlapping ESTs. The EST database (dbEST), which is known and available to those skilled in the art, comprises approximately one million different human mRNA sequences comprising from about 500 to 1000 nucleotides, and various numbers of ESTs from a number of different organisms. dbEST can be accessed through the Internet at, for example, http://www.ncbi.nlm.nih.jzov/dbEST/index. html. These sequences are derived from a cloning strategy that uses cDNA expression clones for genome sequencing. ESTs have applications in the discovery of new genes, mapping of genomes, and identification of coding regions in genomic sequences. Another important feature ofEST sequence information that is becoming rapidly available is tissue-specific gene expression data. This can be extremely useful in targeting selective gene(s) for therapeutic intervention. Since EST sequences are relatively short, they must be assembled in order to provide a complete sequence. Because every available clone is sequenced, it results in a number ofoverlapping regions being reported in the database. The end result is the elicitation of alternative transcript forms from, for example, normal cells and cancer cells. [0021]
Assembly of overlapping ESTs extended along both the 5′and 3′directions results in a full-length “virtual transcript.” The resultant virtual transcript may represent an already characterized nucleic acid or may be a novel nucleic acid with no known biological function. The Institute for Genomic Research (TIGR) Human Genome Index (HGI) database, which is known and available to those skilled in the art, contains a list of human transcripts. TIGR can be accessed through the Internet at, for example, [0022] http://www.tigr.orv/. The transcripts were generated in this manner using TIGR-Assembler, an engine to build virtual transcripts and which is known and available to those skilled in the art. TIGR-Assembler is a tool for assembling large sets of overlapping sequence data such as ESTs, BACs, or small genomes, and can be used to assemble eukaryotic orprokaryotic sequences. TIGR-Assembler is described in, for example, Sutton, et aL, Genome Science & Tech., 1995, 1, 9-19, which is incorporated herein by reference in its entirety, and can be accessed through the Internet at, for example, ftp://ftip.tiizr.org/pub/software/TIGR assembler. In addition, GLAXO-MRC, which is known and available to those skilled in the art, is another protocol for constructing virtual transcripts. In addition, “Find Neighbors and Assemble EST Blast” protocol, which runs on a UNIX platform, has been developed by Applicants to construct virtual transcripts. PAP is used for sequence assembly within Find Neighbors and Assemble EST Blast. PHRAP can be accessed through the Internet at, for example, http:H/chimera.biotech. washington.edu/uwac/tools/phrap.htm. Identification of ESTs and generation of contiguous ESTs to form full length RNA molecules is described in detail in U.S. application Ser. No. 09/076,440, which is incorporated herein by reference in its entirety.
The members of a set of mRNA molecules are compared. Preferably, the set of mRNA molecules is a set of alternative transcript forms of mRNA. Preferably, the members ofthe set of alternative transcript forms ofRNA include at least one member which is associated, or whose encoded protein is associated, with a disease state or biological condition. For example, a set of mRNA molecules for the mdm2 oncogene are compared. At least one ofthe members of the set of mRNA alternative transcript forms is associated with cancer, as described above. Thus, comparison ofthe members ofthe set of mRNA molecules results in the identification of at least one alternative transcript form of RNA which is associated, or whose encoded protein is associated, with a disease state or biological condition. In a preferred embodiment of the invention, the members of the set of mRNA molecules are from a common gene. In another embodiment of the invention, the members of the set of mRNA molecules are from a plurality of genes. In another embodiment of the invention, the members of the set of mRNA molecules are from different taxonomic species. Nucleotide sequences of a plurality of nucleic acids from different taxonomic species can be identified by performing a sequence similarity search, an ortholog search, or both, such searches being known to persons of ordinary skill in the art. [0023]
Sequence similarity searches can be performed manually or by using several available computer programs known to those skilled in the art. Preferably, Blast and Smith-Waterman algorithms, which are available and known to those skilled in the art, and the like can be used. Blast is NCBI′s sequence similarity search tool designed to support analysis of nucleotide and protein sequence databases. Blast can be accessed through the Internetat, for example, [0024] http://www.ncbi.nlm.nih.gov/BLAST/. The GCGPackage provides a local version of Blast that can be used either with public domain databases or with any locally available searchable database. GCG Package v9.0 is a commercially available software package that contains over 100 interrelated software programs that enables analysis of sequences by editing, mapping, comparing and aligning them. Other programs included in the GCG Package include, for example, programs which facilitate RNA secondary structure predictions, nucleic acid fragment assembly, and evolutionary analysis. In addition, the most prominent genetic databases (GenBank, EMBL, PIR, and SWISS-PROT) are distributed along with the GCG Package and are fully accessible with the database searching and manipulation programs. GCG can be accessed through the Internet at, for example, http://www.gcg.com/. Fetch is a tool available in GCG that can get annotated GenBank records based on accession numbers and is similar to Entrez. Another sequence similarity search can be performed with GeneWorld and GeneThesaurus from Pangea. GeneWorld 2.5 is an automated, flexible, high-throughput application for analysis of polynucleotide and protein sequences. GeneWorld allows for automatic analysis and annotations of sequences. Like GCG, GeneWorld incorporates several tools for homology searching, gene finding, multiple sequence alignment, secondary structure prediction, and motif identification. GeneThesaurus 1.Otm is a sequence and annotation data subscription service providing information from multiple sources, providing a relational data model for public and local data.
Another alternative sequence similarity search can be performed, for example, by BlastParse. BlastParse is a PERL script running on a UNIX platform that automates the strategy described above. BlastParse takes a list of target accession numbers of interest and parses all the GenBank fields into “tab-delimited” text that can then be saved in a “relational database” format for easier search and analysis, which provides flexibility. The end result is a series of completely parsed GenBank records that can be easily sorted, filtered, and queried against, as well as an annotations-relational database. [0025]
Preferably, the plurality of nucleic acids from different taxonomic species which have homology to the target nucleic acid, as described above in the sequence similarity search, are further delineated so as to find orthologs of the target nucleic acid therein. An ortholog is a term defined in gene classification to refer to two genes in widely divergent organisms that have sequence similarity, and perform similar functions within the context of the organism. In contrast, paralogs are genes within a species that occur due to gene duplication, but have evolved new functions, and are also referred to as isotypes. Optionally, paralog searches can also be performed. By performing an ortholog search, an exhaustive list of homologous sequences from as diverse organisms as possible is obtained. Subsequently, these sequences are analyzed to select the best representative sequence that fits the criteria for being an ortholog. An ortholog search can be performed by programs available to those skilled in the art including, for example, Compare. Preferably, an ortholog search is performed with access to complete and parsed GenBank annotations for each of the sequences. Currently, the records obtained from GenBank are “flat-files”, and are not ideally suited for automated analysis. Preferably, the ortholog search is performed using a Q-Compare program. Preferred steps of the Q-Compare protocol are described in the flowchart set forth in U.S. Ser. No. 09/076,440, incorporated herein by reference. [0026]
Preferably, interspecies sequence comparison is performed using Compare, which is available and known to those skilled in the art. Compare is a GCG tool that allows pair-wise comparisons of sequences using awindow/stringency criterion. Compare produces an output file containing points where matches of specified quality are found. These can be plotted with another GCG tool, DotPlot. [0027]
Once the members of the set of mRNA molecules are compared, at least one molecular interaction site from among those that are present in the members of the set is identified. The molecular interaction site is present in the alternative transcript form of the rMRNA which is likely associated, or whose encoded protein is likely associated, with a disease state or biological condition. The molecular interaction site is identified by procedures well known to the skilled artisan. The molecular interaction site can be identified based on the nucleic acid sequence of the particular alternative transcript form of the mRNA or can be based on secondary structures presented within the alternative transcript form of the mRNA. [0028]
Molecular interaction sites are small, usually less than 30 nucleotides, independently folded, functional subdomains contained within a larger RNA molecule. Determining whether a particular alternative transcript form contains a molecular interaction site based on secondary structure can be performed by a number of procedures known to those skilled in the art. Determination of secondary structure is preferably performed by self complementarity comparison, alignment and covariance analysis, secondary structure prediction, or a combination thereof. [0029]
In one embodiment ofthe invention, secondary structure analysis is performed by alignment and covariance analysis. Numerous protocols for alignment and covariance analysis are known to those skilled in the art. Preferably, alignment is performed by ClustalW, which is available and known to those skilled in the art. ClustalW is a tool for multiple sequence alignment that, although not a part of GCG, can be added as an extension of the existing GCG tool set and used with local sequences. ClustalW can be accessed through the Internet at, for example, [0030] http://2://dot.imien.bcm.tmc.edu:933 1/multi-align/Options/clustalw.html.
ClustalW is also described in Thompson, et aL, [0031] Nuc. AcidsRes., 1994, 22, 4673-4680, which is incorporated herein by reference in its entirety. These processes can be scripted to automatically use conserved UTR regions identified in earlier steps. Seqed, a UNIX command line interface available and known to those skilled in the art, allows extraction of selected local regions from a larger sequence. Multiple sequences from many different species can be clustered and aligned for further analysis.
Covariation is a process of using phylogenetic analysis of primary sequence information for consensus secondary structure prediction. Covariation is described in the following references, each of which is incorporated herein by reference in their entirety: Gutell, etal., “Comparative Sequence Analysis OfExperiments PerformedDuringEvolution” In Ribosomal RNA Group I Introns, Green, Ed., Austin:Landes, 1996; Gautheret, et al., [0032] Nuc. Acids Res., 1997, 25, 1559-1564; Gautheret, etal., RNA, 1995, 1, 807-814; Lodmell, etal., Proc. Natl. Acad. Sci. USA, 1995, 92, 10555-10559; Gautheret, et al., J Mol. Biol., 1995, 248, 27-43; Gutell, Nuc. Acids Res., 1994, 22, 3 502-3 517; Gutell, Nuc. Acids Res., 1993, 21, 3055-3074; Gutell, Nuc. Acids Res., 1993, 21, 3051-3054; Woese, Proc. Natl. Acad Sci. USA, 1989, 86, 3119-3122; and Woese, et al., Nuc. Acids Res., 1980, 8, 2275-2293. Preferably, covariance software is used for covariance analysis. Preferably, Covariation, a set of programs for the comparative analysis of RNA structure from sequence alignments, is used. Covariation uses phylogenetic analysis of primary sequence information for consensus secondary structure prediction. Covariation can be obtained through the Internet at, for example, http://www.mbio.ncsu.edu/RNaseP/info/2rograms/projrams.html. A complete description of aversion of the program has been published (Brown, J. W. 1991 Phylogenetic analysis of RNA structure on the Macintosh computer. CABIOS7:391-393). The current version is v4. 1, which can perform various types of covariation analysis from RNA sequence alignments, including standard covariation analysis, the identification of compensatory base-changes, and mutual information analysis. The program is well-documented and comes with extensive example files. Compiled as a stand-alone program; it does not require Hypercard (although a much smaller ‘stack’ version is included). This program will run in any Macintosh environment running MacOS v7.1 or higher. Faster processor machines (68040 or PowerPC) is suggested for mutual information analysis or the analysis of large sequence alignments.
In another embodiment of the invention, secondary structure analysis is performed by secondary structure prediction. There are a number of algorithms that predict RNA secondary structures based on thermodynamic parameters and energy calculations. Preferably, secondary structure prediction is performed using either M-fold or RNA Structure 2.52. M-fold can be accessed through the Internet at, for example, [0033] http ://www. ibc.wustl .edu/- zuker/ma/form2.cgi or can be downloaded for local use on UNIX platforms. M-fold is also available as a part of GCG package. RNA Structure 2.52 is a windows adaptation of the M- fold algorithm and can be accessed through the Internet at, for example, http://128. 151. 176.70/RNAstructure.html.
In another embodiment of the invention, secondary structure analysis is performed by self complementarity comparison. Preferably, self complementarity comparison is performed using Compare, described above. More preferably, Compare can be modified to expand the pairing matrix to account for G-U or U-G basepairs in addition to the conventional Watson-Crick G-C/C-G or A-U/U-A pairs. Such a modified Compare program (modified Compare) begins by predicting all possible base-pairings within a given sequence. As described above, a small but conserved region, preferably a UTR, is identified based on primary sequence comparison of a series of orthologs. In modified Compare, each of these sequences is compared to its own reverse complement. Allowable base-pairings include Watson-Crick A-U, G-C pairing and non-canonical G-U pairing. An overlay of such self complementarity plots of all available orthologs, and selection for the most repetitive pattern in each, results in a minimal number of possible folded configurations. These overlays can then used in conjunction with additional constraints, including those imposed by energy considerations described above, to deduce the most likely secondary structure. [0034]
A result of the secondary structure analysis described above, whether performed by alignment and covariance, self complementarity analysis, secondary structure predictions, such as using M-fold or otherwise, is the identification of secondary structure in other alternative transcript forms. Exemplary secondary structures that may be identified include, but are not limited to, bulges, loops, stems, hairpins, knots, triple interacts, cloverleafs, orhelices, ora combination thereof. Alternatively, new secondary structures may be identified. [0035]
In another embodiment of the invention, once the secondary structure of the conserved region has been identified, as described above, at least one structural motif molecular interaction site is identified. These structural motifs correspond to the identified secondary structures described above. For example, analysis of secondary structure by self complementation may provide one type of secondary structure, whereas analysis by M-fold may provide another secondary structure. All the possible secondary structures identified by secondary structure analysis described above are, thus, represented by a family of structural motifs. [0036]
Once the secondary structure(s) of the target nucleic acids, as well as the secondary structures of nucleic acids from different taxonomic species, have been identified, further alternative transcript forms of mRNAs can be identified by searching on the basis of structure, rather than by primary nucleotide sequence, as described above. Additional alternative transcript forms which have secondary structure similar or identical to the secondary structure found as described above can be identified by constructing a family of descriptor elements for the structural motifs described above, and identifying other nucleic acids having secondary structures corresponding to the descriptor elements. The combination of any or all of the nucleic acids having secondary structure can be compiled into a database. The entire process can be repeated with a different target nucleic acid to generate a plurality of different secondary structure groups which can be compiled into the database. Thus, databases of molecular interaction sites can be compiled by performing by the invention described herein. [0037]
After the hypothetical structure motifs are determined from the secondary structure analysis described above, a family of structure descriptor elements is constructed, as described in U.S. Ser. No. 09/076,440, which is incorporated herein by reference in its entirety. Preferably, the structural motifs described above are converted into a family of descriptor elements. One skilled in the art is familiar with construction of descriptors. Structure descriptors are described in, for example, Laferriere, et al., Comput. 4ppl. Biosci., 1994, 10, 211-212, incorporated herein by reference in its entirety. A different structure descriptor element is constructed for each of the structural motifs identified from the secondary structure analysis. Briefly, the secondary structure is converted to a generic text string. For novel motifs, further biochemical analysis such as chemical mapping or mutagenesis may be needed to confirm structure predictions. Descriptor elements may be defined to have various stringency. In addition, the descriptor elements can be defined to allow for a wobble. Thus, descriptor elements can be defined to have any level of stringency desired by the user. [0038]
After a family of structure descriptor elements is constructed, nucleic acids having secondary structure which correspond to the structure descriptor elements are identified. Preferably, nucleic acids having secondary structure which correspond to the structure descriptor elements are identified by searching at least one database, performing clustering and analysis, identifying orthologs, or a combination thereof. Thus, the identified alternative transcript forms have secondary structure which falls within the scope of the secondary structure defined by the descriptor elements. Thus, the identified alternative transcript forms have secondary structure identical to nearly identical, depending on the stringency of the descriptor elements, to the alternative transcript forms previously identified. [0039]
In one embodiment of the invention, nucleic acids having secondary structure which correspond to the structure descriptor elements are identified by searching at least one database. Any genetic database can be searched. Preferably, the database is a UTR database, which is a compilation of the untranslated regions in messenger RNAs. A UTR database is accessible through the Internet at, for example, ftp:Hlarea.ba.cnr.it/pub/embnet/database/utr/. Preferably the database is searched using a computer program, such as, for example, Rnamot, a UNIX-based motif searching tool available from Daniel Gautheret. Each “new” sequence that has the same motif is then queried against public domain databases to identify additional sequences. Results are analyzed for recurrence of pattern in UTRs of these additional ortholog sequences, as described below, and a database of RNA secondary structures is built. One skilled in the art is familiar with Rnamot. Briefly, Rnamot takes a descriptor string and searches any Fasta format database for possible matches. Descriptors can be very specific, to match exact nucleotide(s), or can have built-in degeneracy. Lengths of the stem and loop can also be specified. Single stranded loop regions can have a variable length. G-U pairings are allowed and can be specified as a wobble parameter. Allowable mismatches can also be included in the descriptor definition. Functional significance is assigned to the motifs if their biological role is known based on previous analysis. [0040]
In another embodiment of the invention, the nucleic acids identified by searching databases such as, for example, searching a UTR database using Rnamot, are clustered and analyzed so as to determine their location within the genome. The results provided by Rnamot simply identify sequences containing the secondary structure but do not give any indication as to the location of the sequence in the genome. Clustering and analysis is preferably performed with ClustalW, as described above. [0041]
In another embodiment of the invention, after clustering and analysis is performed as described above, orthologs are identified as described above. However, in contrast to the orthologs identified above, which were solely identified on the basis of their primary nucleotide sequences, these new orthologous sequences are identified on the basis of structure using the nucleic acids identified using Rnamot. Identification of orthologs is preferably performed by BlastParse or Q-Compare, as described above. In embodiments of the invention in which a database containing prokaryotic molecular interaction sites is compiled, it is preferable to refrain from finding human orthologs or, alternatively, discarding human orthologs when found. [0042]
Once the molecular interaction site of an alternative transcript form which is associated to a disease state or biological condition is identified, the nucleic acid sequence from said molecular interaction site is ascertained by routine methodology. The nucleic acid sequences, in turn, can be used to design targeting biomolecules, such as, for example, oligonucleotides, peptide nucleic acid molecules, ribozymes, and small molecules, which interact with the molecular interaction site. The methods of the invention further include contacting the nucleic acid sequence with biomolecules, such as, for example, an oligonucleotide or small molecule. The biomolecules preferably comprise toxin molecules. While there are a number of ways to prepare biomolecules comprising toxins, preferred methodologies are described in a U.S. patent application filed on even date herewith and assigned to the assignee of this invention. This application bear U. S. Serial No. filed on even date herewith assigned attorney docket number IBIS-00 10, which is incorporated by reference herein in its entirety. [0043]
The following examples are meant to be exemplary of embodiments of the invention and are not meant to be limiting.[0044]

EXAMPLES

EXAMPLE 1:

Molecular target in RNA formed from alternative initiation and splicing of the mdm2 oncogene

The mdm2 oncogene has been associated with a variety ofhuman cancers. The protein encoded by mdn2 physically binds to the anti-oncogene p53 protein and interferes with its function as a tumor suppressor. The net result of suppression of a tumor suppressor is tumorigenesis. It was recently discovered that many tumor cells have greatly increased levels or mdm2 protein without a proportionate increase in mdm2 mRNA levels, suggesting that regulation of protein levels occurs downstream of transcription. It was discovered that cancer cells contain a form ofthe mdm2 mRNA that is different in the 5′-untranslated region. Both the normal and cancer-specific forms of the transcript encode an identical protein, since the heterogeneity is found upstream of the initiation of translation on the message. [0045]
The cancer-specific mdm2 RNA was found to contain tree classes of unique structures shown in the box on the lower left side of the illustration. The first structure, shown labeled “unique exon structure” in FIG. 2, derives from unique sequences in [0046] Exon 1 that are not included in the mdm2 transcript found in normal cells. This structure contains two unique internal loops separated by a stack of 5 base pairs and adjacent to a cytosine rich stem loop. Analysis of all mRNA transcripts in the current release of genbank reveals that this structure is unique to the cancer-specific mdm2 transcript.
The second unique structure is found 3′to the first structure is shown in red and blue. It is comprised of mRNA originating from [0047] Exons 1 and 3, which are uniquely found adjacent to each other in the cancer-specific form. This structure, which is also unique, can only exist where these exons are spliced together because it contains parts of each.
The right hand structure in the box is derived exclusively from mRNA that is from [0048] Exon 3. This structure could potentially exist in both the cancer and normal forms of the message. However, in the normal form, this RNA is part of a different structure which is disfavored in the Exon 1/Exon3 junction form.

EXAMPLE 2:

The HER2/neu receptor in carcinoma cells

The HER2 proto-oncogene encodes a protein that binds to the membrane of the cell and transduces signals through a tyrosine kinase activity. This protein has clearly demonstrated association with breast cancer. A product that targets this protein with a monoclonal antibody (Herceptin) has recently been approved for use by the FDA for the treatment of breast cancer. [0049]
It is known that the HER2 receptor mRNA exists in at least two forms (Mol. Cell. Biology 1993,2247-2257, which is incorporated herein by reference in its entirety). The two transcript forms are generated from alternative use of a splice site located 2050 nucleotides downstream from the start of the mRNA. In some cases the splice site is used to generate a transcript greater than 4,000 nucleotides. At other times, the splice site is not used. When it is not used, polyadenylation site downstream of the splice junction triggers termination and polyadenylation of the mRNA. An in-frame stop codon is then used to terminate the protein during translation. The truncated form of the protein contains the extracellular domain of the normal protein without the membrane anchor domain, which results in a secreted rather than a cell associated protein. Transfection studies have shown that the truncated form of HER2 produces a protein that is released from the cell results in resistance to the growth inhibiting effects of the monoclonal antibody used in cancer treatment. Thus, cells producing the truncated form of the mRNA are undesired because they may play a role in resistance to an otherwise useful drug. [0050]
The truncated form of the transcript contains unique structures not found in the normal form (see, FIG. 3). The structure on the left is a portion of the normal form and the truncated form is on the right. The arrow indicated the location of the divergence between the two forms. [0051] Helical structures 1 and 2 are common to both transcript forms. Helicies 4 from both forms are comprised of RNA that is, in part, common to both forms and unique to each form. Thus, helix 4 in the truncated form is a unique target for proximity trigger technology, as is 5, 6 and 7 which are unique to the truncated form. Helix 3 is another example of a structure that is comprised of RNA sequence that is common to both forms of the RNA, but still different in shape as a result of the sequences around it. It is also a useful target for proximity trigger technology.
1 4 1 199 RNA Homo sapiens 1 gaaacugggg agucuugagg gacccccgac uccaagcgcg aaaaccccgg auggugagga 60 gcagggaaau gugcaauacc aacaugucug uaccuacuga uggugcugua accaccucac 120 agauuccagc uucggaacaa gagacccugg uuagaccaaa gccauugcuu uugaaguuau 180 uaaagucugu uggugcaca 199 2 199 RNA Homo sapiens 2 caguggcgau uggaggguag accugugggc acggacgcac gccacuuuuu cucugcugau 60 ccaggcaaau gugcaauacc aacaugucug uaccuacuga uggugcugua accaccucac 120 agauuccagc uucggaacaa gagacccugg uuagaccaaa gccauugcuu uugaaguuau 180 uaaagucugu uggugcaca 199 3 201 RNA Homo sapiens 3 ccccagcggu gugaaaccug accucuccua caugcccauc uggaaguuuc cagaugagga 60 gggcgcaugc cagccuugcc ccaucaacug cacccacucc uguguggacc uggaugacaa 120 gggcugcccc gccgagcaga gagccagccc ucugacgucc aucgucucug cggugguugg 180 cauucugcug gucguggucu u 201 4 195 RNA Homo sapiens 4 ccccagcggu gugaaaccug accucuccua caugcccauc uggaaguuuc cagaugagga 60 gggcgcaugc cagccuugcc ccaucaacug cacccacucg ugaguccaac ggucuuuuuc 120 uccagaaagg aggacuuucc uuucaggggu cuuucugggg cucuuacuau aaaaggggac 180 caacucuccc uuugu 195

Claims

What is claimed is:

1. A method of identifying a target nucleic acid sequence, said nucleic acid sequence being predictive of a preselected disease state or biological condition in cells containing the nucleic acid sequence comprising;

comparing members of a set of mRNA molecules from a common gene, but containing different sequences and structures, said gene being predictive of said disease state or biological condition in cells containing the gene;

identifying at least one molecular interaction site from among those present in said members of the set; said molecular interaction site being present in cells likely to have said disease state or biological condition; and

ascertaining a nucleic acid sequence from said molecular interaction site.

2. The method of claim 1 wherein said molecular interaction site is common among a plurality of said members.

3. The method of claim 1 wherein said gene is vestigial.

4. The method of claim 1 wherein said gene codes for no protein essential for maintenance of the cells or of the disease state or condition.

5. The method of claim 1 further comprising contacting said nucleic acid sequence with an oligonucleotide or small molecule.

6. The method of claim 5 wherein said oligonucleotide gives rise to a cell killing event in cells containing said target nucleic acid sequence.

7. The method of claim 1 wherein said disease state is a hyperproliferative condition.

8. The method of claim 1 wherein said disease state is neoplastic.

9. The method of claim 1 wherein said disease state is a cancerous state.

10. The method of claim 1 wherein said disease state is Lupus erythematosis.

11. The method of claim 1 wherein said disease state is psoriasis.

12. The method of claim 1 wherein said set of members of mRNA molecules includes molecules from non-human animals.